Development and in vitro/in vivo evaluation of a nanosponge formulation loaded with Boswellia carterii oil extracts for the enhanced anti-inflammatory activity for the management of respiratory allergies

Abstract

Abstract Purpose In several nations, it has been known that Boswellia carterii (BC) plants have a long history of usage as an anti-inflammatory medicine. Our current study deals with the study of two different ways of extraction of BC volatile oil and fixed oil as main constituents (Octyl acetate, 46.46% and β-Boswellic acid, 10.21%, respectively), preparation, and evaluation of Nano sponges loaded with either dexamethasone (DEX) or B. carterii volatile/fixed oil mixture. Methods Nano sponges were created utilizing an ultrasound-assisted synthesis method. Using spectrophotometry, the entrapment efficiency (EE%) of drugs in Nano sponges was considered. Several techniques were used to characterize Nano sponges. Results EE% of drugs inside Nano sponges ranged from 99.15 ± 3.50 to 100% ± 4.76%. Particle size of Nano sponges ranged from 59.9 ± 26.3 to 229.2 ± 30.23 nm. Drugs released from Nano sponges bi-phasically according to Korsmeyer–Peppas model. The anti-inflammatory activity of either B. carterii oil mixture or Dexa salt and their Nano formulations (D4 and O1) in the treatment of respiratory allergy were evaluated in rat model mimicking chronic allergic respiratory diseases. Histopathologic examinations and measurement of Intracellular adhesion molecule-1 (ICAM-1), Leukotriene B4 (LTB4) and Interleukin β4 (ILβ4) levels exposed that, the treatment significantly lowered the levels of the inflammatory biomarkers in treated rats and exhibited improved histopathologic profiles when compared to positive control group. Conclusion Boswellia oil and its Nano sponge formulation O1 as well as Dexa salt Nano sponge formulation D4 had promising therapeutic effects on upper and lower respiratory allergic conditions.